Revenue: As of FY2025 Q3, the actual value is USD 0.EPS: As of FY2025 Q3, the actual value is USD -0.7.EBIT: As of FY2025 Q3, the actual value is USD -21.54 M.<h3>Segment Revenue</h3><ul><li>Government Grant Revenue: No revenue was recognized for the three and nine months ended September 30, 2025, compared to $75,000 and $100,000 for the same periods in 2024, respectively.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: For the three months ended September 30, 2025, the net loss was $22.2 million, compared to $2.5 million for the same period in 2024. For the nine months ended September 30, 2025, the net loss was $27.3 million, compared to $7.0 million for the same period in 2024.</li><li>Research and Development Expenses: Increased by $311,000 or 76% during the three months ended September 30, 2025, and by $200,000 or 15% during the nine months ended September 30, 2025, compared to the same periods in 2024.</li><li>General and Administrative Expenses: Increased by $20.2 million or 2636% during the three months ended September 30, 2025, and by $20.4 million or 941% during the nine months ended September 30, 2025, compared to the same periods in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: For the nine months ended September 30, 2025, net cash used was $11.1 million, compared to $1.8 million for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: For the nine months ended September 30, 2025, net cash provided was $14.9 million, compared to $1.8 million for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Gain on Change in Fair Value of Warrant Liabilities: A gain of $884,000 was recognized during the three and nine months ended September 30, 2025, with no comparable gain in 2024.</li><li>Loss on Change in Fair Value of Digital Assets: A loss of $28,000 was recognized during the three and nine months ended September 30, 2025, with no comparable loss in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to continue its research and development efforts, focusing on the commercialization of the Lumee Oxygen and Lumee Glucose platforms in Europe and the United States. The company is also working towards meeting regulatory requirements in Europe to commercialize the Lumee Oxygen reader by early 2026.</li><li>Non-Core Business: The company is exploring additional financing options through the sale of common stock and executing further tranches of the PIPE Subscription Agreement to support operating expenses and product development.</li></ul>

PROFUSA INC. C/WTS 02/08/2027 (TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 0